Last updated: April 24, 2026
Futibatinib: Supplier Landscape for Key Drug-Product Inputs
Who manufactures futibatinib API and where does supply concentrate?
Futibatinib is marketed as Lytgobi (futibatinib) by QED Therapeutics and is manufactured through vertically integrated and contract manufacturing chains typical for oncology oral small molecules. Public supply disclosures for API and finished-dose components are limited in the open record, so supplier identification relies on (i) regulator-facing labels and (ii) drug master file and commercial supply chain disclosures that are not consistently published at the raw-material level.
Result: The open patent-and-regulatory record does not provide a complete, auditable list of specific commercial API and excipient suppliers by name for futibatinib.
What excipients and delivery components typically define the finished tablet supply chain?
For an oral kinase inhibitor tablet, the finished-dose supply chain typically spans:
- Core excipients (binder, disintegrant, lubricant, glidant)
- Film-coating system (polymer, plasticizer, colorants)
- Tablet packaging materials (bottles/closures or blister components)
- Analytical reference standards (futibatinib and related impurities)
Result: The open record does not provide a definitive, supplier-by-name roster for each of these inputs for futibatinib tablets.
What do patents indicate about upstream manufacturing and intermediates?
Futibatinib patents disclose synthetic routes and intermediates (structure-based claims and process claims), which map to what the upstream supplier must be able to manufacture and analyze: key intermediates, final API synthesis, and impurity control strategies. These filings support a process capability view (what suppliers must do) rather than a company-by-company vendor list (who supplies).
What is the actionable supplier view for futibatinib procurement?
Given incomplete public visibility into named suppliers for API and excipients, procurement teams typically use these supplier filters to qualify vendors:
- API contract manufacturers with kinase-inhibitor small-molecule experience and validated impurity control for furano/heteroaryl-rich chemotypes.
- Excipients and coating suppliers that can support controlled particle size distributions, trace metal specs, and consistent polymorphic behavior impacts for oncology oral solids.
- Packaging suppliers with validated moisture ingress control for tablets requiring stability under specified humidity/temperature conditions.
- Analytical testing labs (internal or CMO lab networks) capable of impurity profiling by HPLC and method qualification for regulatory release and stability.
Result: This is the highest-confidence supplier characterization available from the open record.
Key Takeaways
- The open patent-and-label record for futibatinib does not yield a complete, auditable list of named suppliers for API and finished-dose excipients/coating/packaging.
- Public documents support a process-capability view (what types of intermediates and impurity control must be manufactured) rather than a company roster.
- For procurement decisions, qualify suppliers against the molecule-specific manufacturing and testing constraints implied by futibatinib’s synthesis and regulatory release needs.
FAQs
-
Can I name specific API suppliers for futibatinib from public sources?
No complete named list is available in the open record with enough specificity for an auditable procurement mapping.
-
Do futibatinib patents identify intermediate suppliers?
They identify intermediates and synthetic routes, not specific commercial supplier companies.
-
Which parts of the supply chain matter most for futibatinib finished product?
API quality (impurities and polymorphic/solid-state behavior), tablet excipients and coatings (stability and dissolution), and moisture-controlled packaging.
-
Where do procurement teams typically source supplier names when the open record is limited?
From CMO/MAH technical supply agreements, drug master files, and regulatory submissions that are not consistently public at the supplier-name level.
-
What screening criteria should be used to qualify API vendors for futibatinib?
Kinase-inhibitor small-molecule experience, validated impurity control for route-specific byproducts, and capability for method transfer and stability testing support.
References
[1] FDA. “Drug Label: Lytgobi (futibatinib).” U.S. Food and Drug Administration.
[2] QED Therapeutics. “Lytgobi (futibatinib) prescribing information.” United States Package Insert.
[3] Patent literature on futibatinib synthesis and intermediates (process and composition-of-matter filings associated with futibatinib).
